Combination of three drugs slows the progression of advanced kidney cancer
Introduction to study results
Researchers have found that adding a targeted kinase inhibitor to a combination of two immunotherapies can slow the progression of advanced kidney cancer in patients who have not been treated before.
The study was conducted by Dr. Toni Choueiri of the Dana-Farber Cancer Institute.
Understand the process: COSMIC-313
The COSMIC-313 study investigated the combination of the kinase inhibitor cabozantinib with the checkpoint blockers nivolumab and ipilimumab in the treatment of advanced renal cell carcinoma (RCC).
This type of cancer is often associated with moderate or low risk, so effective treatment is crucial. The results of this study were published May 10 in the New England Journal of Medicine.
Study results: A significant impact on progression-free survival
Patients who received the three-drug combination experienced significantly improved progression-free survival.
This means that their cancer did not get worse over a longer period of time compared to those who received only the two immunotherapy drugs.
This improvement resulted in a 27% reduced risk of cancer progression or death for patients who received the three-drug combination.
The specific length of progression-free survival has not yet been determined for the three-drug group.
However, the median progression-free survival for patients who received only nivolumab and ipilimumab was 11.3 months.
Why this study is important
This study is the first to evaluate the benefits of using three treatments, including cabozantinib, compared to just two immuno-oncology treatments.
The aim was to find out whether adding cabozantinib could improve outcomes for patients with advanced RCC.
according to dr For Choueiri, the early results offer a significant benefit for progression-free survival. They also provide a clear picture of the efficacy and safety profile of this three-drug regimen.
Continuation of the process and future implications
At this point in the trial, there was no significant survival benefit for the three-drug combination. Therefore, the study will proceed to the next phase, which is to analyze overall survival.
The study enrolled 855 previously untreated patients with advanced or metastatic renal cell cancer.
According to the International Metastatic RCC Database Consortium (IMDC) risk model, they had an intermediate or low risk of survival.
Cabozantinib, nivolumab, and ipilimumab work together to inhibit cancer-promoting signaling pathways and enhance response to checkpoint inhibitors.
This combination could offer significant benefit in the treatment of advanced kidney cancer.
The results of the study were previously presented at the ESMO Congress 2022 in Paris.
If you care about the health of your kidneys, please read studies on how to protect your kidneys from diabetes and scientists will find the key to treating kidney disease.
For more information on kidney health, see recent studies on how to live long with kidney disease. Frequent painkillers can damage your heart, kidneys, and more.
The study was published in the New England Journal of Medicine.
Copyright © 2023 Knowridge Science Report. All rights reserved.